Welcome! This is the NEW free version of the SciBITES Pharma News Engine from SciBite. By using this site you to accept our Terms & Conditions which the use of cookies to enhance your user experience.


Here is the latest news for your query in chronological order, most recent articles at the top. Use the options on the right to filter and customise this news feed.

  Todays Biosimilar (Tag) Articles ...

EMA Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting, European Medicines Agency, London, UK, From: 15-Mar-2017, To: 15-Mar-2017
http://www.ema.europa.eu, , 27-Mar-2017
PDA Biosimilars Conference 2017
http://www.biosimilarnews.com, , 27-Mar-2017
EMA Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting, European Medicines Agency, London, UK, From: 15-Mar-2017, To: 15-Mar-2017
Double-blind, Randomized, Multicenter, Phase III Clinical Study to Compare the Efficacy and to Evaluate the Safety and Immunogenicity of Trastuzumab Biosimilar HLX02 and EU-sourced Herceptin® in HER2-Positive, Locally Recurrent or Previously Untreated Metastatic Breast Cancer
ClinicalTrials.gov, , 27-Mar-2017
Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany.
Medline, Patient preference and adherence [11] 519-530, 25-Mar-2017
Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product.
Medline, Open access rheumatology : research and reviews [9] 29-35, 25-Mar-2017
Efficacy and safety of biosimilar epoetin alpha in patients with chronic lymphoid neoplasms and chemotherapy-induced anaemia: An observational, retrospective, monocentric analysis.
Medline, Hematological oncology, 25-Mar-2017
[Long-acting insulins in the treatment of type 2 diabetes and their position in the current treatment algorithm].
Medline, Vnitrni lekarstvi [63] 87-92, 25-Mar-2017

  This Weeks Biosimilar (Tag) Articles ...

Amgen wins European approval for Humira biosimilar Amgevita
http://www.pmlive.com, , 24-Mar-2017
Amgen’s Amgevita secures approval in Europe for certain inflammatory diseases
http://regulatoryaffairs.pharmaceutical-business-review.com, , 24-Mar-2017
FDA Approves First-ever Merkel Cell Carcinoma Drug, HTGM Riding High, FLXN Soars
Bing Pharma News, NASDAQ [nasdaq.com], 24-Mar-2017
A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs
ClinicalTrials.gov, , 24-Mar-2017
Global Biosimilar Insulin Market Opportunity & Clinical Insight Outlook 2022
http://www.prnewswire.com, , 22-Mar-2017
The Path of Interchangeability of Biosimilars in Pediatric Inflammatory Bowel Disease: Quality Before Cost-Savings.
Medline, Journal of pediatric gastroenterology and nutrition, 22-Mar-2017
Biosimilars: Considerations for Oncology Nurses
.
Medline, Clinical journal of oncology nursing [21] E54-E60, 22-Mar-2017
Biosimilars in psoriasis: the future or not?
Medline, Cutis [99] 116-120, 22-Mar-2017
A new decade of disruption: meeting the biosimilar challgenge
http://www.pmlive.com, , 21-Mar-2017

  Older Biosimilar (Tag) Articles ...

Biosimilars: implications for rheumatoid arthritis therapy.
Medline, Current opinion in rheumatology, 19-Mar-2017
aTyr Pharma Inc LIFE Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 23022017] Prices from USD $250
Bing Pharma News, bioportfolio.com, 18-Mar-2017
FDA Transparency: Agency’s Hands Tied by its own Regulations
Bing Pharma News, raps.org, 18-Mar-2017
Showing Records 0 ... 20  


SciBite
The Language Of Science

SciBite provides text-analytics and data intelligence software for drug discovery, clinical and competitor intelligence and much more for pharma, healthcare and life sciences.

This is a Limited, Free Service only touching the surface of how SciBite's tools transform biomedical text, literature, patents, internal documents and news into a rich intelligence network. If you'd like to know more, contact us to see how our tools can transform your work today!

Topic Activity & Tools

Get Daily Alerts!

Click For Email & RSS Alerts

About/Links

Name: Biosimilar (Tag)
Type: Technology

Filters

Source:


Must Mention A:


In Context:


Insights

Show Most Frequent


Optional, Only Include Source:


Tools

[Not available (Why?)]